Systemic chemotherapy (SC) before cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).

Milovanov, Vladimir; Sardi, Armando; Ledakis, Panayotis; Aydin, Nail; Jimenez, William; Sittig, Michelle; MacDonald, Ryan; Gushchin, Vadim

doi:10.1200/jco.2014.32.15_suppl.e15179

Cited by 13 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For patients who are candidates for cytoreductive surgery (CRS) and HIPEC, systemic chemotherapy can be used preoperatively, postoperatively, or both 24,26,30 . According to standards used in other colorectal cancer settings, a combined total of 6 months of chemotherapy is usually recommended.…”

Section: Principles Of Systemic Chemotherapymentioning

confidence: 99%

The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms

Schuitevoerder¹,

Plana²,

Izquierdo³

et al. 2020

Cancer

Self Cite

View full text Add to dashboard Cite

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. Cancer 2020;126:2525-2533.

show abstract

Section: Principles Of Systemic Chemotherapymentioning

confidence: 99%

The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms

Schuitevoerder¹,

Plana²,

Izquierdo³

et al. 2020

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, its combination with bevacizumab might contribute to prolonged PFS. With respect to neoadjuvant [19,[56][57][58][59][60][61][62][63][64] and adjuvant [57,[65][66][67] chemotherapy, no definite survival benefits were proven in low-grade PMP, high-grade PMP, or high-grade PMP with signet ring cells, which is quite controversial. According to the PSOGI expert panel, neoadjuvant or adjuvant chemotherapy should not be totally abandoned in low-grade PMP (92.7% and 74.5%, respectively) and can be considered in patients with high-grade PMP with signet ring cells (76.4% and 85.5%, respectively).…”

Section: Controversies On Systemic Chemotherapiesmentioning

confidence: 99%

Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines

Lin

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background Pseudomyxoma peritonei (PMP) is a clinical malignant syndrome mainly originating from the appendix, with an incidence of 2–4 per million people. As a rare disease, an early and accurate diagnosis of PMP is difficult. It was not until the 1980s that the systematic study of this disease was started. Main body As a result of clinical and basic research progress over the last 4 decades, a comprehensive strategy based on cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) has been established and proved to be an effective treatment for PMP. Currently, CRS + HIPEC was recommended as the standard treatment for PMP worldwide. There are several consensuses on PMP management, playing an important role in the standardization of CRS + HIPEC. However, controversies exist among consensuses published worldwide. A systematic evaluation of PMP consensuses helps not only to standardize PMP treatment but also to identify existing controversies and point to possible solutions in the future. The controversy underlying the consensus and vice versa promotes the continuous refinement and updating of consensuses and continue to improve PMP management through a gradual and continuous process. In this traditional narrative review, we systemically evaluated the consensuses published by major national and international academic organizations, aiming to get a timely update on the treatment strategies of CRS + HIPEC on PMP. Conclusion Currently, consensuses have been reached on the following aspects: pathological classification, terminology, preoperative evaluation, eligibility for surgical treatment, maximal tumor debulking, CRS technical details, and severe adverse event classification system. However, controversies still exist regarding the HIPEC regimen, systemic chemotherapy, and early postoperative intraperitoneal chemotherapy.

show abstract

“…A potential survival advantage for patients with signet ring cell PMP in the neoadjuvant setting has been seen in a retrospective study. 35 Neoadjuvant systemic therapy could be considered in young patients with borderline resectable high-grade PMP in an effort to decrease tumour load preoperatively, keeping in mind that about 29% will respond, but 50% might progress while on therapy. 36 In the palliative context, typical systemic chemotherapy regimens used in colorectal cancer with the addition of bevacizumab can be considered in high-grade tumours.…”

Section: Systemic Chemotherapymentioning

confidence: 99%

“…There is very little evidence that systemic chemotherapy has an impact on survival for patients with any type of PMP treated by CRS + HIPEC. A potential survival advantage for patients with signet ring cell PMP in the neoadjuvant setting has been seen in a retrospective study 35 . Neoadjuvant systemic therapy could be considered in young patients with borderline resectable high‐grade PMP in an effort to decrease tumour load preoperatively, keeping in mind that about 29% will respond, but 50% might progress while on therapy 36 .…”

Section: Management Of Specific Clinical Scenarios and Histologic Finmentioning

confidence: 99%

Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review

Soucisse

Lansom

Alshahrani

et al. 2020

ANZ Journal of Surgery

View full text Add to dashboard Cite

Mucinous appendiceal neoplasms (MANs) are rare tumours and the primary cause of pseudomyxoma peritonei. These tumours have a much more benign course than typical colorectal cancers, generally growing for many years before giving any clinical signs. The spectrum of presentations, tumour stages and the underlying cytology is very wide, warranting from the simplest operation like an appendicectomy to the most complicated operation like a complete cytoreduction surgery and hyperthermic intraperitoneal chemotherapy. Fortunately, most patients can be offered a curative treatment, but limiting operative morbidity without compromising oncologic outcomes is the biggest challenge in managing these patients. Histopathology is the cornerstone of decision making for MANs, but is also subject to ongoing debate because of a lack of terminology consensus amongst pathologists. Combined with the rarity of this disease, the multiple histopathologic classification updates of MANs explain the ongoing confusion amongst clinicians in regard to individual optimal treatment. This review will cover the most recent histological classification of MANs and attempt to clarify optimal management of patients with different clinical presentation and histologic combinations.

show abstract

Systemic chemotherapy (SC) before cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).

Cited by 13 publications

References 0 publications

The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms

The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms

Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines

Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review

Contact Info

Product

Resources

About